Up 260% so far this year, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity thanks to its increasingly promising therapies in development to treat obesity. But as wise investors know, buying a small biotech stock immediately after it has significantly gained in value can be a especially risky proposition.

So is it too late to invest in this company, or are the good times just getting started?

There are two distinct arguments for why it's already too late to buy Viking Therapeutics. According to the first argument, the company's clinical-stage programs for obesity and other cardiometabolic illnesses like metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) are all perfectly well and good from an investment standpoint.

Continue reading

Source Fool.com